Evotec SE stock (DE0005664809): focus on valuation after bond placement and activist deal

Evotec SE shares on Xetra were broadly stable after the recent €116.1 million convertible bond placement and an agreement with an activist investor, keeping attention on the German biotech group's valuation metrics and balance sheet ahead of the June 11 annual general meeting.

Evotec SE shares traded largely steady on Xetra on 05/28/2026, with the stock quoted around 4.99 EUR in Frankfurt afternoon trading as investors continued to digest the company’s recent €116.1 million convertible bond placement and an agreement with an activist investor ahead of the June 11 annual general meeting, according to finanzen.ch as of 05/28/2026 and coverage on ad-hoc-news.de referencing the same developments.finanzen.ch as of 05/28/2026ad-hoc-news.de as of 05/28/2026

Germany-based Evotec SE, listed on Xetra under the ticker EVT, placed the €116.1 million zero-coupon convertible bonds earlier in May 2026 to support liquidity and fund a €75 million cost-cutting and transformation program, as described in a company announcement cited by Morningstar and summarized in an overview article on ad-hoc-news.de that also highlighted a sharp year-on-year drop in first-quarter revenue.Morningstar as of 05/28/2026ad-hoc-news.de as of 05/16/2026

The stock traded at 4.99 EUR on Xetra on 05/28/2026, while the U.S.-listed American depositary shares under ticker EVO last closed at USD 2.96 on Nasdaq on 05/28/2026, according to MarketBeat and Morningstar price data.MarketBeat as of 05/28/2026Morningstar as of 05/28/2026 In Germany, the stock also changes hands on venues such as Tradegate, but Xetra remains the main home-country listing for the biotech group.

Evotec SE recently also reached a cooperation arrangement with an activist investor that opted for partnership over confrontation, according to a detailed report on ad-hoc-news.de describing how the investor supported the convertible bond issue and the cost-cutting plan instead of pushing for a more aggressive breakup or strategic alternatives.ad-hoc-news.de as of 05/16/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Drug discovery and contract research in biopharmaceuticals
• Headquarters/country: Hamburg, Germany
• Core markets: Europe, North America and selected Asia-Pacific partnerships
• Key revenue drivers: Integrated drug discovery collaborations, development partnerships and milestone/royalty streams with pharmaceutical and biotech partners
• Home exchange/listing venue: Xetra (EVT)
• Trading currency: EUR

Evotec SE: core business model

Evotec generates most of its income by acting as a partnered research and development platform for pharmaceutical and biotechnology companies, combining fee-for-service work with milestone and royalty structures on co-discovered drug candidates.

Valuation metrics and multiples for Evotec SE

With the valuation focus on Friday, investors are looking at how Evotec SE is priced relative to its fundamentals after the convertible bond issue and the share price performance of the past months. While precise up-to-the-minute earnings-based valuation ratios for the German listing are best derived from the company’s most recent financial statements, data compiled by Morningstar for the U.S. listing under ticker EVO shows that the stock traded around USD 4.08 earlier in May 2026, compared with a Morningstar fair value estimate of USD 5.91 for that line, implying a notable discount to the research provider’s long-term assessment at that time.Morningstar as of 05/12/2026

MarketBeat reports that, as of late May 2026, four Wall Street analysts covering the Nasdaq-listed shares had an average 12-month price target of USD 7.00, with the current price of USD 2.96 on 05/28/2026 implying potential upside from that consensus if the business delivers on its pipeline and restructuring plans; however, those targets refer to the U.S. line and do not represent a formal valuation for the German shares.MarketBeat as of 05/28/2026 For investors following the Xetra listing, implied valuation levels will also depend on the euro share price, exchange rate effects and any updated guidance from the company once the cost-cutting program progresses.

Conclusion

Evotec SE enters the June 11 annual general meeting in Germany with a reinforced balance sheet from the €116.1 million convertible bond issue, a cooperative stance from an activist investor and a share price on Xetra that has recently traded just under 5 EUR amid lingering questions about profitability after a weaker first quarter. The valuation picture for the U.S.-listed shares, with a current price of USD 2.96 against a MarketBeat consensus target of USD 7.00 as of late May 2026, underlines how much of the investment case depends on the successful execution of the restructuring and the progress of partnered research programs rather than near-term earnings multiples.MarketBeat as of 05/28/2026 The coming quarters, including further updates via the company’s investor relations channel and Xetra trading data, will be important for assessing how the market ultimately prices Evotec SE’s pipeline, platform and new cost base.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.